The burgeoning landscape of emerging treatments for body management has seen the rise of both retatrutide and tirzepatide, both dual mechanism agonists targeting the GLP-1 and GIP receptors. While sharing a comparable https://socialmphl.com/story22914541/retatrutide-vs-tirzepatide-a-comparative-analysis